Introduction of alternative models of the research process as a way to reduce the life cycle of pharmaceutical innovation

In this article author considers the possibility of time and resources saving by applying alternative bio-models. It is shown that, in spite of the existing experience and strong economic arguments of applying the latest technologies, there are many risks to be considered while choosing the research model. Continuous evaluation should be made to make adequate conclusions of prognostic effects of innovative medicines for humans.